Clinical Trial Update: A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of KAN-101 in celiac disease was terminated, with results posted on 2026-03-10.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• KAN-101

Snippet

Sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | Conditions: Celiac Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-03-10